Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Require Disclosure of Clinical R&D Costs in More Detail
December 15, 2014
- JMA, JAMS Call for Enhancing Support for Girls Suffering from Post-HPV Vaccine Reactions
December 12, 2014
- JPMA President Opposes Annual NHI Price Revision
November 21, 2014
- PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium
November 20, 2014
- Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs
November 20, 2014
- Mr Aoyagi of JPMA Calls for Negotiating Invoice Prices for Individual Products
November 17, 2014
- No Nippon Pharmacy Association Affiliated Pharmacy Will Be Subject to Medical Fee Cut Rule: Survey
November 17, 2014
- JPMA, JPPA, and JPWA Express Strong Opposition to Annual NHI Price Revision
November 4, 2014
- EFPIA Japan Official Calls for More-Effective Use of Surplus Raw Plasma
October 30, 2014
- April-June Generic Share at 49.8% under New Formula: JGA
October 29, 2014
- JPMA to Launch Compound Library Joint Purchasing Initiative; Full-Scale Purchasing to Begin in FY2015
October 29, 2014
- FPMAJ Sets Up Panel to Discuss Selective Sales Tax Breaks
October 27, 2014
- Japan CRO Association Nearing Remote Verification Agreement with Cancer Treatment Center
October 22, 2014
- JPMA Tones Down Demand on R&D Tax Credit System, Calls for “Maintenance” Instead of “Perpetuation”
October 20, 2014
- JMA Pres. Frets Proposed Introduction of Reference Pricing Rule
October 17, 2014
- JPMA Decides on More Close-Up Disclosure for R&D Outlays
October 17, 2014
- Industry Associations Call for Delay in Ratification of COP10 Nagoya Protocol
October 10, 2014
- US Nonprofit ACRES Launches Japan Branch
October 8, 2014
- National University Hospital Council’s Guidelines Not to Require Disclosure of Individuals’ Names
October 7, 2014
- JPMA Plans Disclosure of Recipients, Amount of Payments for R&D Outlays
October 3, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…